Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Clinicopathological characteristics of included breast samples

From: BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers

  BRCA1-C BRCA2-C Sporadic-C BRCA1-N BRCA2-N Non-BRCA- related-N p ValueA
n % n % n % n % n % n %
Number of samples (%) 39 23.5 33 19.9 80 48.2 5 3 4 2.4 5 3  
Age, years           9.56°10−9
 Median 43 N/A 46 N/A 58 N/A 31 N/A 36.5 N/A 22 N/A 0.549B
 Range 30–80 N/A 21–69 N/A 29–86 N/A 29–33 N/A 35–38 N/A 18–52 N/A  
GradeC           0.00007*ǂǂ
 1 0 0 1 3 20 25.3     
 2 9 23.1 10 30.3 25 31.6     
 3 30 76.9 22 66.7 34 43     
Tumor type           0.230ǂǂ
 Ductal 34 87.2 29 87.9 69 86.3     
 Lobular 2 5.1 2 6.1 10 12.5     
 Other 3 7.7 2 6.1 1 1.3     
ER           0.0004*ǂǂǂ
 Negative 26 66.7 8 24.2 23 28.8     
 Positive 13 33.3 25 75.8 57 71.3     
PR           0.001*ǂǂǂ
 Negative 29 74.4 17 51.5 30 37.5     
 Positive 10 25.6 16 48.5 50 62.5     
HER2           0.68ǂǂ
 Negative 38 97.4 32 97 75 93.8     
 Positive 1 2.6 1 3 5 6.3     
  1. Abbreviations: BRCA1-C Breast carcinomas from BRCA1 germline mutation carriers, BRCA2-C Breast carcinomas from BRCA2 germline mutation carriers, BRCA1/2-N Normal breast tissue from BRCA1 and BRCA2 germline mutation carriers, ER Estrogen receptor, Non-BRCA-related-N Normal breast tissue from patients not known to have a BRCA1 or BRCA2 germline mutation, HER2 Human epidermal growth factor receptor 2, N/A Not available, PR Progesterone receptor, Sporadic-C Sporadic breast carcinoma
  2. ATesting BRCA1-C and BRCA2-C together against Sporadic-C
  3. BTesting BRCA1-N and BRCA2-N together against non-BRCA-related N
  4. CFor 1 of 80 sporadic breast cancer cases, the grade was unknown
  5. ǂMann-Whitney U test
  6. ǂǂFisher’s exact test
  7. ǂǂǂPearson’s chi-square test
  8. *Statistically significant (two-sided p value <0.05)